Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design

Importance: Pregnancy induces unique physiologic changes to the immune response and hormonal changes leading to plausible differences in the risk of developing post-acute sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy may also have long-term ramifications for exposed offspring, and it is critical to evaluate the health outcomes of exposed children. The National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER-Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads. Methods: RECOVER-Pregnancy cohort is a combined prospective and retrospective cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19 pandemic and their offspring exposed and unexposed in utero, including single and multiple gestations. Enrollment will occur both in person at 27 sites through the Eunice Kennedy Shriver National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through national recruitment by the study team at the University of California San Francisco (UCSF). Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated screening tools, laboratory analyses and symptom questionnaires followed by more in-depth phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later analyses proposed by RECOVER and other investigators. Discussion: RECOVER-Pregnancy will address whether having SARS-CoV-2 during pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort will also establish whether there are increased risks of adverse long-term outcomes among children exposed in utero. Registration: NCT05172024

has been found to be protective against both severe maternal COVID-19 and adverse 167 pregnancy outcomes, and may also influence the incidence of PASC in this population. [9][10][11] . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. ; https://doi.org/10.1101/2023.04.24.23289025 doi: medRxiv preprint 168 The National Institute of Health's (NIH) RECOVER initiative has a unique opportunity to 169 study the post-acute sequelae of SARS-CoV-2 acquired in pregnancy. RECOVER-Pregnancy 170 will enroll maternal-child dyads to investigate the effects of SARS-CoV-2 acquired during 171 pregnancy on the long-term health of both the pregnant person and their offspring who were 172 exposed to SARS-CoV-2 in utero. We hypothesize that the incidence of persistent long-term 173 sequelae among pregnant people will vary from that of non-pregnant adults given the unique 174 changes in physiology, hormone levels, and inflammatory milieu in pregnancy. In addition, we 175 hypothesize that the offspring of individuals with SARS-CoV-2 infection in pregnancy will have 176 worse developmental outcomes when compared with unexposed offspring delivered over the 177 same time period. The overarching goal of RECOVER-Pregnancy is to describe PASC in 178 people who are infected with SARS-CoV-2 in pregnancy and examine the outcomes of their 179 offspring compared with children who were not exposed to SARS-CoV-2 in utero.

181
Objectives 182 RECOVER-Pregnancy cohort will enroll maternal-child dyads exposed and unexposed 183 to SARS-CoV-2 during pregnancy, with pregnant individuals participating in RECOVER-Adult 184 and offspring participating as the in utero exposed subgroup of RECOVER-Pediatric. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 24, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. group for all analyses examining outcomes of the offspring, as the offspring will not be exposed 293 in utero. However, some of the enrolled adult pregnancy participants who were enrolled as 294 uninfected controls will acquire SARS-CoV-2 infection during the 4-year longitudinal follow-up 295 period. These participants will cross over to the infected group for the adult cohort, and will be 296 analyzed as infected in analyses assessing only the adult outcomes from that time period 297 forward, but their offspring will remain in the unexposed pediatric cohort. Thus, the RECOVER 298 Data Resource Center (DRC) will classify pregnant individuals with SARS-CoV-2 and their 299 offspring intentionally and separately for each analysis depending on the outcome being 300 examined.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. Questionnaire (BISQ) 29 is also collected at 24 months of age.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

388
Other Tier 2 assessments include anthropometric measurements, such as child weight, 389 length/height, and head circumference measured using well calibrated, quality instruments and 390 standardized techniques, to ultimately assess child weight trajectories, weight status and 391 cardiometabolic risk. A sample of blood will be obtained at 24 months for SARS-CoV-2 antibody 392 testing and central biobanking. Blood will be collected at 24 months by a trained and 393 experienced pediatric phlebotomist, or through remote at-home collection using a TASSO M20 394 device, which collects capillary blood using 4 volumetric sponges that each hold 17.5µL of blood 395 (70 µL total). If using the Tasso M20 device, one sponge is used for SARS-CoV-2 spike and 396 nucleocapsid antibody testing and remaining sponges are banked for future use. If using in-397 person phlebotomy, EDTA and SST tubes will be collected ensuring that the total blood volume 398 is less than 2 mL per kg of body weight.

399
Data collection, management and quality assurance reporting a symptom at a given follow-up time point among those remaining in RECOVER, will . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. follow-up visits relative to the end of pregnancy, will be considered.

423
Measures of child physical health and behavioral and developmental outcomes will be 424 summarized in the in utero exposure to SARS-CoV-2 cohort overall and by maternal infection 425 status during pregnancy. Two-sample, two-sided t-tests will be used to compare cross-sectional 426 means of continuous outcomes between groups, and chi-squared tests will be used to compare 427 categorical outcomes between groups. Multivariable linear and generalized linear regression 428 models will also be fit to adjust for relevant baseline factors that are different between groups.

429
For outcomes measured at multiple visits, trajectories will be modeled and compared using 430 linear and generalized linear mixed effects models.

431
Safety and possible risks 432 All RECOVER activities are approved by a single institutional review board (IRB), which 433 is the New York University IRB. All of the RECOVER-Pregnancy sites will establish reliance on . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. and DP-4) will be provided to the caregiver of the participant with a recommendation to follow-451 up with the child's primary health care provider. Ranges of concern will be determined by 452 psychologists and developmental-behavioral pediatricians, and standardized across the cohort.

454
The NIH RECOVER-Pregnancy cohort will answer critical questions regarding the 455 incidence and trajectory of PASC following SARS-CoV-2 infection during pregnancy, and the 456 effects of in utero exposure to SARS-CoV-2 infection on offspring development. There are little . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted April 24, 2023. found an association between exposure to SARS-CoV-2 in utero and neurodevelopmental 470 diagnoses, but was limited by the possibility of ascertainment bias, because those exposed to 471 SARS-CoV-2 may have been more likely to be followed and referred. 32 The RECOVER-

472
Pregnancy study will add to this available evidence by comparing children who were SARS-

473
CoV-2 exposed with contemporaneous unexposed controls, and following them longitudinally 474 over time. The RECOVER-Pregnancy study will also be able to examine for potential 475 differences in subsets of the population exposed to SARS-CoV-2 in utero, such as by trimester 476 of infection, or by maternal disease severity and treatments for SARS-CoV-2.

477
The design of the pregnancy cohort provides several strengths. Enrollment of maternal-478 child dyads across the U.S. will increase generalizability of study results, enhance racial, ethnic, 479 and socioeconomic diversity, and enable collection of detailed information on both the mother 480 and the child to enable robust analyses. SARS-CoV-2 is known to have disproportionately 481 affected Black and Latino communities (especially early in the pandemic) 33, 34 ; thus, the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 24, 2023. ; https://doi.org/10.1101/2023.04.24.23289025 doi: medRxiv preprint 503 Acknowledgements 504 We would like to thank the National Community Engagement Group (NCEG), all patient, 505 caregiver and community representatives, and all the participants enrolled in the RECOVER 506 initiative.

507
Membership of the RECOVER Initiative is provided in a supplemental appendix file.

508
Supporting Information

509
The supporting information is provided in a supplemental appendix file.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 24, 2023. concurrently.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 24, 2023. ; https://doi.org/10.1101/2023.04.24.23289025 doi: medRxiv preprint